Cell-Based Therapy for Neural Disorders - Anticipating Challenges

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 744-752

  Chiu, Arlene Y ^a   Rao, Mahendra S ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Life Technologies Corporation   (United States)

Author keywords

CNS roadblocks; ESC; Pluripotent stem cells

Indexed keywords

DRUG VEHICLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL COUNT; CELL DEATH; CELL MIGRATION; CELL THERAPY; EMBRYONIC STEM CELL; ENZYME REPLACEMENT; INFLAMMATORY INFILTRATE; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELIN DEFICIENCY; NEOPLASM; NEURAL STEM CELL TRANSPLANTATION; NEUROLOGIC DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SPINAL CORD INJURY; STROKE;

ANIMALS; CELL DIFFERENTIATION; HUMANS; NERVOUS SYSTEM DISEASES; STEM CELLS; TISSUE THERAPY;

EID: 80955143473     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0066-9     Document Type: Review

References (27)

1. Dranovsky A, Picchini AM, Moadel T, et al. Experience dictates stem cell fate in the adult hippocampus. Cell 2011; 70: 908-923.
2. Wieloch T, Nikolich K. Mechanisms of neural plasticity following brain injury. Curr Opinion in Neurobiology 2006; 16: 258-264.
3. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science 2010; 330: 1238-1240.
4. Busch SA, Hamilton JA, Horn KP, et al. Multipotent adult progenitor cells prevent macrophage-mediated axonal dieback and promote regrowth after spinal cord injury. J Neurosci 2011: 31: 944-953.
5. Horn KP, Busch SA, Hawthorne AL, van Rooijen N, Silver J. Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. J Neurosci 2008; 28: 9330-9341.
6. Pfisterer U, Kirkeby A, Torper O, et al. Direct conversion of human fibroblasts to dopaminergic neurons. PNAS USA 2011; 108: 10343-10348.
7. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
8. Lindvall O, Bjorklund A. Cell therapy in Parkinson's disease. NeuroRx 2004; 1: 382-393.
9. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing doamine neurons in Parkinson's disease. Trends Pharmacol Sci 2009; 30: 260-267.
10. Aboody K, Capela A, Niazi N, Stern JH, Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta Stone Neuron 2011; 70: 597-613.
11. Carpenter MK, Frey-Vasconcells J, Rao MS. Developing safe therapies from human pluripotent stem cells. Nature Biotech 2009; 27: 606-613.
12. Ahrlund-Richter L, De Luca M, Marshak DR, Munsie M, Veiga A, Rao M. Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell 2009; 4: 20-26.
13. Rao M. Conserved and divergent paths that regulate self-renewal in mouse and human embryonic stem cells. Developmental Biol 2004; 275: 269-286.
14. Gilbert S. The morphogenesis of evolutionary developmental biology. Int J Dev Biol 2003; 47: 467-477.
15. Maitra A, Arking DE, Shivapurkar N, et al. Genomic alterations in cultured human embryonic stem cells. Nature Genet 2005; 37: 1099-1103.
16. Zeng X, Rao MS. Human embryonic stem cells: long term stability, absence of senescence and a potential cell source for neural replacement. Neuroscience 2007; 145: 1348-1358.
17. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nature Biotech 2003; 21: 319-321.
18. Xue H, Wu S, Papadeas ST, et al. A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. Stem Cells 2009; 27: 1836-1846.
19. Zeng X, Rao MS. Controlled genetic modification of stem cells for developing drug discovery tools and novel therapeutic applications. Curr Opin Mol Ther 2008; 10: 207-213.
20. Kamb A. Consequences of nonadaptive alterations in cancer. Mol Biol Cell 2003: 14: 2001-2005.
21. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-216.
22. Awano T, Johnson GS, Wade CM, et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. PNAS USA 2009; 106: 2794-2799.
23. Matsumoto A, Okada Y, Nakamichi M, et al. Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res 2006; 83: 119-133.
24. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
25. Huang Y, Enzmann V, Ildstad ST. Stem cell-based therapeutic applications in retinal degenerative diseases. Stem Cell Rev 2011; 7: 434-445.
26. Frank RT, Najbauer J, Aboody KS. Concise review: stem cells as an emerging platform for antibody therapy of cancer. Stem Cells 2010; 28: 2084-2087.
27. Gutova M, Najbauer J, Chen MY, Potter PM, Kim SU, Aboody KS. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme. Curr Stem Cell Res Ther 2010; 5: 273-276.